News tagged with braf
New factor to control oncogene-induced senescence
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...
Cancer
16 hours ago |
not rated yet |
0
New mutations driving malignant melanoma discovered
Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't ...
Cancer
Jan 24, 2013 |
not rated yet |
0
|
Study uncovers mechanism by which melanoma drug accelerates secondary skin cancers
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers at UCLA's ...
Cancer
Jan 18, 2012 |
5 / 5 (1) |
0
|
ASCO: Trametinib improves survival in metastatic melanoma
(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with ...
Cancer
Jun 05, 2012 |
not rated yet |
0
Scientists uncover mechanism for melanoma drug resistance
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.
Cancer
Mar 06, 2012 |
5 / 5 (4) |
0
|
Study offers clues to cause of kids' brain tumors
(Medical Xpress)—Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children.
Genetics
Nov 16, 2012 |
5 / 5 (1) |
0
|
Dabrafenib shrinks melanoma brain metastases in phase I clinical trial
An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of ...
Cancer
May 17, 2012 |
not rated yet |
0
|
Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.
Cancer
Jul 16, 2012 |
not rated yet |
0
|
Research shows promising treatments against skin cancer
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.
Cancer
Jun 04, 2012 |
not rated yet |
0
RNA regulator of melanoma could be a new target for cancer therapy
Melanoma is the most deadly form of skin cancer, estimated by the National Cancer Institute to afflict more than 70,000 people in the United States annually and the incidence rate continues to rise. In a study published online ...
Cancer
May 10, 2012 |
5 / 5 (1) |
0
|
Second mutation in BRAF-mutated melanoma doesn't contribute to resistance
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.
Cancer
Apr 01, 2012 |
5 / 5 (1) |
0
|
Combo therapies tested to overcome drug resistance in melanoma patients
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit ...
Cancer
Aug 02, 2011 |
not rated yet |
0
|
Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma
Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to data presented at the ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Preclinical study indicates potential for novel inhibitor to overcome drug resistance induced by RAF, MEK inhibitors
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...
Cancer
Apr 08, 2013 |
not rated yet |
0
TGen professor discusses benefits of whole genome sequencing in study of multiple myeloma
The scientific benefits of whole genome sequencing at the Translational Genomics Research Institute (TGen) will be presented at the 14th International Myeloma Workshop, April 3-7 at the Kyoto International Conference Center.
Cancer
Apr 03, 2013 |
not rated yet |
0
